Education
About Us
Working with TipRanks
Follow Us
Cantargia AB (SE:CANTA)
:CANTA
CANTA Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr1.14 - kr5.20
Previous CloseN/A
Volume611.88K
Average Volume (3M)976.30K
Market Cap
€323.20M
Enterprise ValueN/A
Total Cash (Recent Filing)kr33.04M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.70
Next Earnings
May 13, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.21
Shares Outstanding248,611,650
10 Day Avg. Volume417,505
30 Day Avg. Volume976,299
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
---
CANTA FAQ
What was Cantargia AB’s price range in the past 12 months?
Cantargia AB lowest stock price was kr1.14 and its highest was kr5.20 in the past 12 months.
What is Cantargia AB’s market cap?
Cantargia AB’s market cap is €323.20M.
When is Cantargia AB’s upcoming earnings report date?
Cantargia AB’s upcoming earnings report date is May 13, 2025 which is in 18 days.
How were Cantargia AB’s earnings last quarter?
Cantargia AB released its earnings results on Feb 21, 2025. The company reported -kr0.214 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.214.
Is Cantargia AB overvalued?
According to Wall Street analysts Cantargia AB’s price is currently Overvalued.
Does Cantargia AB pay dividends?
Cantargia AB does not currently pay dividends.
What is Cantargia AB’s EPS estimate?
Cantargia AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cantargia AB have?
Cantargia AB has 248,611,650 shares outstanding.
What happened to Cantargia AB’s price movement after its last earnings report?
Cantargia AB reported an EPS of -kr0.214 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.77%.
Which hedge fund is a major shareholder of Cantargia AB?
Currently, no hedge funds are holding shares in SE:CANTA
---
Company Description
Cantargia AB
Cantargia AB is engaged in the development of products used in the treatment of cancer. It has developed specific antibodies against IL1RAP to treat serious, life-threatening diseases. The company's first product candidate, CAN04, has also been designed to treat different forms of cancer, with the initial focus on the treatment of non-small cell lung cancer and pancreatic cancer.
---
Technical Analysis
Oncopeptides AB
―
Xbrane Biopharma AB
―
Isofol Medical AB
―
Guard Therapeutics International AB
―
Immunicum AB
―
---